These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 3093335)

  • 1. Effect of plasma protease inhibitors on tumor cell-induced platelet aggregation.
    Pacchiarini L; Pagliarino M; Rota Scalabrini D; Grignani G; Rizzo SC
    Haematologica; 1986; 71(3):269. PubMed ID: 3093335
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of tumor proteinases in tumor cell-induced platelet aggregation.
    Pacchiarini L; Grignani G; Pagliarino M; Ricetti MM; Bottazzi B; Mantovani A; Ascari E
    Invasion Metastasis; 1986; 6(5):287-301. PubMed ID: 3536793
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prostacyclin, thromboxanes, and hematogenous metastasis.
    Honn KV; Sloane BF
    Adv Prostaglandin Thromboxane Leukot Res; 1983; 12():313-8. PubMed ID: 6221609
    [No Abstract]   [Full Text] [Related]  

  • 4. Study of platelet aggregation in vivo. IX. Effect of nafazatrom on in vivo platelet aggregation and spontaneous tumor metastasis.
    Ambrus JL; Ambrus CM; Gastpar H; Williams P
    J Med; 1982; 13(1-2):35-47. PubMed ID: 6288824
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition by prostacyclin of the tumor cell-induced platelet release reaction and platelet aggregation.
    Menter DG; Onoda JM; Moilanen D; Sloane BF; Taylor JD; Honn KV
    J Natl Cancer Inst; 1987 May; 78(5):961-9. PubMed ID: 3553692
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Inhibition of platelet aggregation and prevention of endotoxin-induced DIC by a protease inhibitor, FUT-175, in rats].
    Yoshikawa T; Murakami M; Furukawa Y; Onodera H; Yoshida N; Ueda M; Kato H; Takemura S; Sugino S; Kondo M
    Masui; 1984 Apr; 33(4):397-402. PubMed ID: 6471360
    [No Abstract]   [Full Text] [Related]  

  • 7. Animal models for the study of platelet-tumor cell interactions.
    Donati MB; Rotillio D; Delaini F; Giavazzi R; Mantovani A; Poggi A
    Prog Clin Biol Res; 1982; 89():159-76. PubMed ID: 7202205
    [No Abstract]   [Full Text] [Related]  

  • 8. [Cancer metastasis and platelet aggregation].
    Tsuruo T
    Tanpakushitsu Kakusan Koso; 1990 Nov; 35(15):2818-24. PubMed ID: 2259729
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro.
    Avcu F; Ural AU; Cetin T; Nevruz O
    Thromb Res; 2008; 121(4):567-71. PubMed ID: 17910980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of heparin in tumor cell-induced platelet aggregation.
    Yamamoto K; Kitagawa H; Tanoue K; Tsuruo T; Yamamoto N; Yamazaki H
    Thromb Haemost; 1986 Aug; 56(1):90-4. PubMed ID: 3095948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Platelet aggregation inhibitors and metastatic spread of neoplastic cells.
    Ambrus JL; Ambrus CM; Gastpar H
    Prog Clin Biol Res; 1982; 89():83-95. PubMed ID: 7111311
    [No Abstract]   [Full Text] [Related]  

  • 12. Interaction of platelets and tumor cells.
    Steiner M
    Prog Clin Biol Res; 1982; 89():383-403. PubMed ID: 7111305
    [No Abstract]   [Full Text] [Related]  

  • 13. Effects of prostacyclin on tumor cell-induced platelet aggregation.
    Menter DG; Onoda JM; Taylor JD; Honn KV
    Cancer Res; 1984 Feb; 44(2):450-6. PubMed ID: 6362850
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of the platelet-aggregating activity of two human adenocarcinomas of the colon and an anaplastic murine tumor with a specific thrombin inhibitor: dansylarginine N-(3-ethyl-1, 5-pentanediyl)amide.
    Pearlstein E; Ambrogio C; Gasic G; Karpatkin S
    Prog Clin Biol Res; 1982; 89():479-502. PubMed ID: 6287488
    [No Abstract]   [Full Text] [Related]  

  • 15. Characterization of the platelet-aggregating activity of tumor cells.
    Hara Y; Steiner M; Baldini MG
    Cancer Res; 1980 Apr; 40(4):1217-22. PubMed ID: 7357551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of plasmin-induced platelet aggregation.
    Watabe A; Ohta M; Matsuyama N; Mizuno K; el Borai N; Tanimoto T; Kawanishi T; Hayakawa T
    Res Commun Mol Pathol Pharmacol; 1997 Jun; 96(3):341-52. PubMed ID: 9261893
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix metalloproteinase 2 in tumor cell-induced platelet aggregation: regulation by nitric oxide.
    Jurasz P; Sawicki G; Duszyk M; Sawicka J; Miranda C; Mayers I; Radomski MW
    Cancer Res; 2001 Jan; 61(1):376-82. PubMed ID: 11196190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of carcinogenesis by protease inhibitors.
    Kennedy AR
    Cancer Res; 1994 Apr; 54(7 Suppl):1999s-2005s. PubMed ID: 8137328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antimetastatic and antitumor effect of platelet aggregation inhibitors.
    Ambrus JL; Ambrus CM; Gastpar H; Huberman E; Montagna R; Biddle W; Leong S; Horoszewicz J
    Prog Clin Biol Res; 1982; 89():97-111. PubMed ID: 7111312
    [No Abstract]   [Full Text] [Related]  

  • 20. Guanidinophenyl derivatives of pyrazole: synthesis and inhibitory effect on serine proteinases, blood coagulation and platelet aggregation.
    Ferroni R; Menegatti E; Scalia S; Orlandini P; Guarneri M; Taddeo U
    Farmaco Sci; 1986 Oct; 41(10):747-57. PubMed ID: 3539635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.